Ondansetron at 1mg/mL is a selective 5-HT3 receptor antagonist that blocks nausea signals at the neurological level — the only prescription antiemetic in the Legere injectable catalog. Available as a standalone injectable and as the active component in the Reboot IV Kit.
Ondansetron is a selective 5-HT3 (serotonin) receptor antagonist that blocks the neural signaling pathways responsible for nausea and vomiting at both the gut and brain level. Originally developed for chemotherapy-induced nausea, it is now widely used across clinical settings for acute nausea from multiple causes — post-surgical, procedure-related, GLP-1 medication side effects, and acute recovery protocols.
At 1mg/mL, injectable Ondansetron provides faster onset than oral formulations — particularly relevant when oral intake is compromised by nausea itself.
| Specification | Detail |
|---|---|
| Active ingredient | Ondansetron HCl |
| Concentration | 1 mg/mL |
| Route | IV, IM, or SQ |
| Storage | Room temperature; protect from light |
Ondansetron selectively blocks 5-HT3 receptors — serotonin receptors found in the chemoreceptor trigger zone (CTZ) of the brain and in vagal nerve terminals in the gut. Both sites are key triggers of the nausea and vomiting reflex. By blocking serotonin at these receptors, Ondansetron interrupts the signal before it reaches the vomiting center in the brainstem.
This mechanism distinguishes it from older antiemetics that work through dopamine blockade — Ondansetron has no dopaminergic activity, meaning it does not cause the extrapyramidal side effects (restlessness, muscle stiffness) associated with those agents.
Acute nausea management: The most direct and effective injectable option for patients presenting with active nausea — faster onset than oral antiemetics when patients cannot reliably retain oral medication.
GLP-1 protocol support: Nausea is the most common side effect of GLP-1 receptor agonist medications (semaglutide, tirzepatide). Practices managing GLP-1 patients increasingly incorporate injectable antiemetic support as a standard protocol component.
Hangover and recovery protocols: A cornerstone of acute recovery IV programs — Ondansetron addresses the nausea component while electrolytes and B-vitamins address dehydration and nutrient depletion simultaneously.
Post-procedure support: Nausea is a common post-procedure complaint after sclerotherapy, aesthetic procedures, and minor surgical interventions. Ondansetron provides rapid, reliable relief without sedation.
Reboot IV Kit — Ondansetron is the active antiemetic component in the Reboot Kit, paired with Mineral Blend and B-Complex for complete acute recovery support. Ordering standalone Ondansetron allows practices to adjust dosing or add it to other IV protocols independently.
Quench IV Kit — For patients presenting with nausea alongside dehydration, adding standalone Ondansetron to a Quench protocol addresses both presenting complaints simultaneously.
B-Complex Injection — Adding B-Complex alongside Ondansetron supports energy and metabolic recovery alongside nausea management, a practical combination for post-illness or post-procedure protocols.
This is the most important clinical consideration for Ondansetron and must be reviewed before ordering.
Ondansetron is associated with dose-dependent QT interval prolongation, which can lead to serious cardiac arrhythmia (Torsades de Pointes). Risk is elevated in patients with:
Screen patients for cardiac history and electrolyte status before administering. Do not use in patients with known QT prolongation risk without appropriate evaluation.
Contraindications:
Significant drug interactions:
Common side effects: Headache, constipation, dizziness, fatigue, drowsiness, injection site reactions.
Serious but rare: Cardiac arrhythmia, serotonin syndrome, severe allergic reaction.
As a compounded Rx product, this formulation of Ondansetron has not been evaluated by the FDA for safety, efficacy, or quality. Administer only under the supervision of a licensed healthcare provider in accordance with current clinical and state regulatory guidelines.
FAQs
Is a prescription required to order Ondansetron Injection?
Yes. Ondansetron is a prescription medication dispensed exclusively to licensed healthcare providers and medical practices. It is not available for direct patient purchase.
What is the concentration and route of administration?
1mg/mL, for IV, IM, or SQ administration.
What is the most critical safety consideration for Ondansetron?
QT interval prolongation — screen patients for cardiac history, long QT syndrome, electrolyte imbalances (low potassium or magnesium), and concurrent QT-prolonging medications before administering. This risk is the primary reason Ondansetron requires provider-level evaluation before use.
How does standalone Ondansetron differ from the Reboot IV Kit?
The Reboot IV Kit includes Ondansetron pre-combined with Mineral Blend and B-Complex for a complete acute recovery protocol. Standalone Ondansetron gives practices the flexibility to add antiemetic support independently to other IV protocols or adjust dosing separately.
This is a compounded medication. Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. This product is available by prescription only and is intended for use by or on the order of a licensed healthcare provider.
Schedule a no obligation/no-pressure call to quickly increase your weight loss clinic’s revenue.
